MedPath

Effect of Virtual Reality-based Therapy on Negative Symptoms in People with Schizophrenia

Not Applicable
Recruiting
Conditions
Schizophrenia
Interventions
Behavioral: Virtual Reality Therapy for the Negative Symptoms of Schizophrenia
Behavioral: Sham- VR
Registration Number
NCT06588270
Lead Sponsor
Hospital de la Florida Dra. Eloiza Diaz
Brief Summary

A randomised, controlled, double-blind clinical trial will be carried out to evaluate the effectiveness of a VR assisted treatment for negative symptoms in people with schizophrenia. Patients with a standardised diagnosis of schizophrenia meeting the inclusion criteria will receive 12 weekly sessions of VR assisted therapy plus treatment as usual (TAU). A control group will be exposed to a neutral VR environment plus TAU. The hypothesis is that patients who are treated with active VR assisted therapy will have less negative symptoms as rated by the PANSS-N scale, compared to the control group.

The protocol was approved by the hospital ethics committee of the Servicio de Salud Metropolitano Suroriente. Patients sign an informed consent form, from which they may withdraw at any point during the intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
102
Inclusion Criteria
  • Diagnosis of schizophrenia made by the treating psychiatrist and corroborated by a team's psychiatrist under CIE-10 criteria.
  • Age between 18 to 65 years-old.
  • Outpatient setting,
  • Clinical stability defined as no psychiatric hospitalizations in the last 6 months and not currently on queue for psychiatric hospitalization.
  • No concomitant active substance abuse disorder, excluding nicotine.
  • Subjects are capable of providing informed consent.
Exclusion Criteria
  • Previous diagnosis of learning disability according either to ICD- 10 or clinical history
  • Verbal expression difficulties, determined by language or medical causes.
  • Deafness and/or blindness.
  • Other physical handicaps to use VR devices.
  • Predominant positive symptoms, defined as PANNS-C > 0.
  • Catatonic symptoms.
  • Previous epilepsy diagnosis.
  • Neurodegenerative disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual reality-based therapyVirtual Reality Therapy for the Negative Symptoms of SchizophreniaThe intervention group will receive a VR experience with a treatment software. The aim is to immerse the patient in an interactive environment that invites him/her to explore and complete goal-directed activities with sensory, visual and/or auditory rewards. The therapy will be delivered with the support of a therapist once per week for 12 consecutive weeks. Each therapy session will last approximately 20 minutes.
Sham -VRSham- VRControl group's patients will continue pharmacological and non pharmacological usual treatment. Additionally, these patients will attend to VR sessions without the software created activities for treatment (sham-VR). Sessions will be the same length and quantity as the intervention group's sessions.
Primary Outcome Measures
NameTimeMethod
Negative symptoms12 weeks

The primary outcome will be the difference in the rate of change in negative symptoms at 3 months of follow-up. Negative symptoms are measured with the Positive and negative syndrome scale (PANSS) negative subscale. Scale's scoring system ranges from 7 to 49 points.

A 25% reduction from the baseline score on the PANSS-N will be considered a significant decrease.

Secondary Outcome Measures
NameTimeMethod
Positive symptoms12 weeks

Positive symptoms are measured with the Positive and negative syndrome scale (PANSS) positive subscale. It consists of seven items: delusions, conceptual disorganization, hallucinations, excitement, grandiosity, suspiciousness/persecution and hostility. Scale's scoring system ranges from 7 to 49 points. No changes from the baseline PANSS-P score are expected.

Mood symptoms12 weeks

Mood symptoms are assessed with the Calgary depression scale for schizophrenia. Scale's scoring system ranges from 0 to 27 points.

Quality of life: Short Form (36) Health Survey12 weeks

The Short Form (36) Health Survey is a self-applied questionnaire that addresses eight life dimensions: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. It will be used to assess quality of life. As it is a dimensional scale, it does not have a cutoff score.

Global functioning12 weeks

Global assessment of functioning (GAF) is a numeric scale of social, occupational and psychological functioning. Scale's scoring system ranges from 10 to 100 points.

Social anxiety12 weeks

Social anxiety symptoms are measured with Social Interaction Anxiety Scale (SIAS). This is a self applied, twenty items instrument. Scale's scoring system ranges from 0 to 80 points.

Adverse effects12 weeks

Adverse effects are measured with the Simulator Sickness Questionnaire (SSQ). This instrument assesses 16 subjective items and was developed to accommodate symptoms specific to simulator technology. It can be self applied or clinician rated. Participants are asked to assign a score from 0-3 for each of the sixteen items on the SSQ. Total scores can be associated with negligible (\< 5), minimal (5 - 10), significant (10 - 15), concerning (15 - 20) and bad (\>20) symptoms.

Trial Locations

Locations (1)

Hospital Clínico La Florida

🇨🇱

Santiago, Chile

© Copyright 2025. All Rights Reserved by MedPath